239 related articles for article (PubMed ID: 22491823)
1. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
2. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
4. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
5. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Beha N; Harder M; Ring S; Kontermann RE; Müller D
Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
7. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Zhang J; Valianou M; Simmons H; Robinson MK; Lee HO; Mullins SR; Marasco WA; Adams GP; Weiner LM; Cheng JD
FASEB J; 2013 Feb; 27(2):581-9. PubMed ID: 23104982
[TBL] [Abstract][Full Text] [Related]
8. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.
Zhen Z; Tang W; Wang M; Zhou S; Wang H; Wu Z; Hao Z; Li Z; Liu L; Xie J
Nano Lett; 2017 Feb; 17(2):862-869. PubMed ID: 28027646
[TBL] [Abstract][Full Text] [Related]
9. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
[TBL] [Abstract][Full Text] [Related]
10. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
12. Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.
Bauer S; Adrian N; Siebenborn U; Fadle N; Plesko M; Fischer E; Wüest T; Stenner F; Mertens JC; Knuth A; Ritter G; Old LJ; Renner C
Cancer Immun; 2009 Mar; 9():2. PubMed ID: 19267427
[TBL] [Abstract][Full Text] [Related]
13. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
[TBL] [Abstract][Full Text] [Related]
14. Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.
Stone JD; Chervin AS; Schreiber H; Kranz DM
Biotechnol Prog; 2012; 28(6):1588-97. PubMed ID: 22961781
[TBL] [Abstract][Full Text] [Related]
15. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
16. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein.
Bauer S; Adrian N; Williamson B; Panousis C; Fadle N; Smerd J; Fettah I; Scott AM; Pfreundschuh M; Renner C
J Immunol; 2004 Mar; 172(6):3930-9. PubMed ID: 15004201
[TBL] [Abstract][Full Text] [Related]
17. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
19. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
20. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
